Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells
(CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic …

Prostate cancer (PCa) has a vast clinical spectrum from the hormone-sensitive setting to
castration-resistant metastatic disease. Thus, chemotherapy regimens and the …

Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the
present immunotherapy era, several immunotherapeutic agents have been evaluated in …

Context Progress achieved in the treatment of prostate cancer (PCa) with surgical, radiation,
and hormonal therapies has drastically reduced mortality from this disease. Yet, patients …

Simple Summary There is still no effective treatment for advanced prostate cancer. CAR-T
therapy is a promising approach; however, many obstacles remain for the treatment of solid …

Simple Summary Prostate cancer is one of the most frequently diagnosed cancers amongst
men worldwide. Treatment for metastatic disease is often in the form of androgen deprivation …

Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of
Science, in part because of the successful treatment of refractory hematological …

Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of
the patient's own T cells so that they specifically recognize and destroy tumour cells …

Simple Summary Prostate cancer is one of the leading causes of cancer-related deaths
among men in the United States and Europe. While conventional treatment options either …

Objective: Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated an
unprecedented therapeutic efficacy in hematological malignancies; however, its …